GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.
Shares of AstraZeneca rose on Friday after the drugmaker reported positive results from late-stage clinical trials of its ...
On 25 March, detailed Phase I trial data was published for ESO-T01, AstraZeneca’s in vivo CAR-T therapy, in patients with ...
By Pushkala Aripaka and Nithyashree R B March 27 (Reuters) - AstraZeneca's experimental drug tozorakimab reduced flare-ups of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results